≡

Monoclonal Antibody to Mitogen Activated Protein Kinase Kinase 1 (MAP2K1)

MAPKK1; MEK1; MKK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; ERK activator kinase 1

  • Product No.MAD559Hu21
  • Organism SpeciesHomo sapiens (Human) Same name, Different species.
  • SourceMonoclonal antibody preparation
  • HostMouse
  • Potency (Clone Number)n/a
  • Ig Isotype IgG
  • PurificationAntigen-specific affinity chromatography followed by Protein A affinity chromatography
  • LabelNone
  • Immunogen n/a
  • Buffer FormulationPBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
  • TraitsLiquid
  • Concentration1mg/mL
  • Organism Species Moren/a
  • ApplicationsWB; IHC; ICC; IP.
    If the antibody is used in flow cytometry, please check FCM antibodies.
  • Downloadn/a
  • UOM 20µl100µl 200µl 1ml 10ml
  • FOB US$ 111  US$ 259  US$ 370  US$ 925  US$ 3700 
    For more details, please contact local distributors!

SPECIFITY

The antibody is a mouse monoclonal antibody raised against MAP2K1. It has been selected for its ability to recognize MAP2K1 in immunohistochemical staining and western blotting.

USAGE

Western blotting: 0.2-2µg/mL;1:500-5000
Immunohistochemistry: 5-20µg/mL;1:50-200
Immunocytochemistry: 5-20µg/mL;1:50-200
Optimal working dilutions must be determined by end user.

STORAGE

Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Graefe's Archive for Clinical and Experimental Ophthalmology Role of RhoA/MERK1/ERK1/2/iNOS signaling in ocular ischemic syndrome pubmed:27538909
PLOS ONE Identification of Biomarkers of Impaired Sensory Profiles among Autistic Patients. pubmed:27824861
Cancers Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia Pubmed: 31718075
Cancers (Basel) BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers 2021, 13, 581 33540760
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPD559Hu01 Recombinant Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) Positive Control; Immunogen; SDS-PAGE; WB.
PAD559Hu01 Polyclonal Antibody to Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) WB; IHC; ICC; IP.
MAD559Hu21 Monoclonal Antibody to Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) WB; IHC; ICC; IP.
SED559Hu ELISA Kit for Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) Enzyme-linked immunosorbent assay for Antigen Detection.
LMD559Hu Multiplex Assay Kit for Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.